➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Medtronic
McKesson
Merck
Express Scripts

Last Updated: February 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ACITRETIN

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Acitretin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002143 Treatment of Psoriasis Using Acitretin in HIV-Positive Patients Completed Hoffmann-La Roche Phase 3 1969-12-31 To determine the efficacy of acitretin in the treatment of psoriasis in HIV/AIDS patients. Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in treating psoriasis in patients without HIV infection by reducing skin involvement and clearing of the condition, but it has not been thoroughly evaluated in HIV-infected patients.
NCT00003611 Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation Completed National Cancer Institute (NCI) N/A 2000-05-01 RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of acitretin may be an effective way to prevent the recurrence or further development of skin cancer. PURPOSE: Randomized clinical trial to study the effectiveness of acitretin in preventing skin cancers in patients with at least two previously treated skin cancers who have undergone organ transplantation.
NCT00003611 Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation Completed Alliance for Clinical Trials in Oncology N/A 2000-05-01 RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of acitretin may be an effective way to prevent the recurrence or further development of skin cancer. PURPOSE: Randomized clinical trial to study the effectiveness of acitretin in preventing skin cancers in patients with at least two previously treated skin cancers who have undergone organ transplantation.
NCT00156247 Acitretin and Etanercept in Psoriasis Completed Connetics Corp. Phase 2 2005-09-01 To determine whether acitretin plus etanercept is more effective than etanercept alone in clearing psoriasis plaques in adults.
NCT00156247 Acitretin and Etanercept in Psoriasis Completed University of Medicine and Dentistry of New Jersey Phase 2 2005-09-01 To determine whether acitretin plus etanercept is more effective than etanercept alone in clearing psoriasis plaques in adults.
NCT00353119 A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis Completed Amgen Phase 3 2006-04-01 Palmoplantar pustulosis (PPP) is a chronic recurrent skin condition characterized by the presence of pustules, erythema and hyperkeratosis on palms and soles. PPP can be a severe and disabling disease limiting the ability to walk or work. Although studies on the quality of life of patients with PPP are not available, a recent investigation showed that palmoplantar psoriasis (non pustular) has a more important impact on quality of life than plaque psoriasis. This important impact on quality of life is not surprising as palmoplantar psoriasis as well as palmoplantar pustulosis may limit the ability to work or conduct activities with hands or even impair walking. The disease is sometimes associated with psoriasis elsewhere on the body. Current treatments for PPP include topical corticosteroids, cyclosporine, PUVA therapy, methotrexate and acitretin. Response to topical corticosteroids and PUVA therapy is often disappointing presumably because the thickness of the stratum corneum on palms and soles prevents good penetration of topical medications and light. Cyclosporine and methotrexate are sometimes used with success for PPP but there are concerns with long term toxicity of both drugs. Therefore there is a need for new treatments for PPP.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Acitretin

Condition Name

Condition Name for Acitretin
Intervention Trials
Psoriasis 13
Plaque Psoriasis 2
HIV Infections 2
Non-melanomatous Skin Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Acitretin
Intervention Trials
Psoriasis 21
Skin Neoplasms 2
HIV Infections 2
Retinal Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Acitretin

Trials by Country

Trials by Country for Acitretin
Location Trials
United States 15
Canada 7
Korea, Republic of 3
China 3
India 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Acitretin
Location Trials
Pennsylvania 3
Arizona 2
New York 2
Utah 1
South Dakota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Acitretin

Clinical Trial Phase

Clinical Trial Phase for Acitretin
Clinical Trial Phase Trials
Phase 4 11
Phase 3 4
Phase 2/Phase 3 1
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Acitretin
Clinical Trial Phase Trials
Completed 14
Unknown status 5
Not yet recruiting 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Acitretin

Sponsor Name

Sponsor Name for Acitretin
Sponsor Trials
Postgraduate Institute of Medical Education and Research 3
Innovaderm Research Inc. 3
Singapore General Hospital 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Acitretin
Sponsor Trials
Other 40
Industry 8
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
McKinsey
Mallinckrodt
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.